Catalyst Wire Dossier Catalyst Wire Dossier

Glesatinib

glesatinib · Mirati Therapeutics Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Glesatinib, covering 2024-04-22 to 2024-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer [Phase 2]

See pricing